ArticleDiabetology & metabolic syndrome2026
Consumption of sugar-sweetened beverages and all-cause mortality and cause-specific mortality: insights from nationwide prospective cohort studies and Global Burden of Disease study 2021.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundSugar-sweetened beverages (SSBs) consumption has become an emerging global public health concern. The relationship between SSBs consumption and mortality is not yet fully clarified. This study aims to quantify the dose-response relationships between SSBs consumption and mortality risks in US and UK cohorts, while also reviewing up-to-date estimates of SSB-related burden from 1990 to 2021 at a national level.
methodsWe conducted a nationwide prospective cohort study and systematic analysis. The study included 13,438 participants from US National Health and Nutrition Examination Survey (NHANES) (1999-2000 and 2017-2018), and 63,436 participants from UK Biobank (2006-2010). For the systematic analysis using Global Burden of Disease (GBD) 2021 data, mortality and disability-adjusted life years (DALYs) for the US and UK (1990-2021) were analyzed to generate estimates.
resultsIn the US population, during a 9.17-year cohort follow-up, 1,929 deaths were identified among 13,438 participants, while in the UK population, during a 12.41-year cohort follow-up, 3,466 deaths were identified among 63,436 participants. A significant dose-response association was found between higher SSBs consumption and increased all-cause mortality (both P for trend < 0.001), as well as mortality due to cardiovascular disease and chronic lower respiratory diseases. In GBD, SSBs-related mortality and DALYs rates were higher in older populations (55 + years) in both countries, consistent with the results in US NHANES and UK Biobank. Ischemic heart disease and type 2 diabetes mellitus were leading contributors to these burdens.
conclusionsThis study establishes a robust relationship between SSBs consumption and all-cause mortality, mortality caused by cardiovascular disease and chronic lower respiratory diseases. In line with GBD findings, SSBs consumption, especially among elderly populations, should be considered a crucial public health concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.